Report cover image

Pulmonary Drug Delivery Systems Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 27, 2025
Length 350 Pages
SKU # EMAR20319743

Description

The global pulmonary drug delivery systems market size was valued at USD 56.90 Billion in 2024 , driven by the increasing incidence of respiratory conditions across the globe. The market size is anticipated to grow at a CAGR of 5.65% during the forecast period of 2025-2034 to achieve a value of USD 98.58 Billion by 2034 .

Pulmonary Drug Delivery Systems: Introduction

Pulmonary drug delivery systems are medical devices or drug formulations designed to deliver medications directly to the lungs through inhalation. These systems are used to treat various respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory infections, among others. Pulmonary drug delivery offers several advantages, including rapid onset of action, targeted drug delivery to the lungs, and reduced systemic side effects compared to oral or intravenous administration.

Global Pulmonary Drug Delivery Systems Market Analysis

The growth of the market is driven by the strategic collaborations between pharma giants to resolve issues together resulting in increased market growth. For example, the strategic partnership between Hovione and H&T Presspart to develop the Sunriser© Capsule-based DPI platform is expected to address the evolving requirements of the pulmonary drug delivery systems market as they offer more efficient and adaptable solutions for inhalable medications. The development of the Sunriser© DPI is expected to result in more efficient and effective delivery of inhalable drugs resulting in enhanced patient compliance and outcomes for various respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD).

The market growth is also driven by increased innovation, coupled with expanded product offerings, and improved drug delivery options for patients. Such collaborations are expected to influence the market greatly as they may result in patient-friendly, efficient, and adaptable inhalation solutions propelling the global pulmonary drug delivery systems market growth.

Global Pulmonary Drug Delivery Systems Market Segmentations

Pulmonary Drug Delivery Systems Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  
  • Jet Nebulizers

    •   
  • Soft Mist Nebulizers

    •   
  • Ultrasonic Nebulizers
    • Others
    Market Breakup by Applications
    • Cystic Fibrosis
    • Asthma
    • Allergic Rhinitis
    • COPD
    • Others
    Market by End User
    • Hospitals
    • Diagnostic Centres
    • Homecare Settings
    • Others
    Market Breakup by Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
    Global Pulmonary Drug Delivery Systems Market Overview

    The global market for pulmonary drug delivery systems is experiencing significant growth driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With these conditions continuing to affect a substantial portion of the global population, there is a growing demand for effective drug delivery systems specifically designed for pulmonary treatments in the market.

    Additionally, advancements in inhalation technologies and drug formulations are also enhancing the efficiency and effectiveness of pulmonary drug delivery, further propelling the pulmonary drug delivery systems market growth.

    Furthermore, the COVID-19 pandemic has highlighted the importance of respiratory health, leading to increased awareness and investments in pulmonary drug delivery systems. The need for efficient administration of respiratory medications, including vaccines and therapies for various lung infections is expected to further drive innovation and development of novel delivery devices in the market, propelling the market growth.

    The increasing geriatric population, particularly in developed countries, is contributing to increased respiratory-related illnesses, further aiding the pulmonary drug delivery systems market demand. As healthcare systems focus on patient-centric care and improved treatment outcomes, the market is witnessing a surge in research and development activities, new product launches, and strategic collaborations. All these factors collectively are boosting the global market and are expected to drive the market in coming years as well.

    Global Pulmonary Drug Delivery Systems Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • Koninklijke Philips NV
    • GlaxoSmithKline PLC
    • 3M
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • AstraZeneca
    • Cipla Inc.
    • Merck & Co.
    • GF Health Products Inc.
    • Aerogen
    • PARI GmbH
    • Gilbert Technologies
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Global Pulmonary Drug Delivery Systems Market Overview
    3.1 Global Pulmonary Drug Delivery Systems Market Historical Value (2018-2024)
    3.2 Global Pulmonary Drug Delivery Systems Market Forecast Value (2025-2034)
    4 Global Pulmonary Drug Delivery Systems Market Landscape
    4.1 Global Pulmonary Drug Delivery Systems Developers Landscape
    4.1.1 Analysis by Year of Establishment
    4.1.2 Analysis by Company Size
    4.1.3 Analysis by Region
    4.2 Global Pulmonary Drug Delivery Systems Product Landscape
    4.2.1 Analysis by Type
    4.2.2 Analysis by Technology
    5 Global Pulmonary Drug Delivery Systems Market Dynamics
    5.1 Market Drivers and Constraints
    5.2 SWOT Analysis
    5.3 Porter’s Five Forces Model
    5.4 Key Demand Indicators
    5.5 Key Price Indicators
    5.6 Industry Events, Initiatives, and Trends
    5.7 Value Chain Analysis
    6 Global Pulmonary Drug Delivery Systems Market Segmentation
    6.1 Global Pulmonary Drug Delivery Systems Market by Product Type
    6.1.1 Market Overview
    6.1.2 Dry Powder Inhalers
    6.1.3 Metered Dose Inhalers
    6.1.4 Nebulizers
    6.1.4.1 Jet Nebulizers
    6.1.4.2 Soft Mist Nebulizers
    6.1.4.3 Ultrasonic Nebulizers
    6.1.5 Others
    6.2 Global Pulmonary Drug Delivery Systems Market by Applications
    6.2.1 Market Overview
    6.2.2 Cystic Fibrosis
    6.2.3 Asthma
    6.2.4 Allergic Rhinitis
    6.2.5 COPD
    6.2.6 Others
    6.3 Global Pulmonary Drug Delivery Systems Market by End User
    6.3.1 Market Overview
    6.3.2 Hospitals
    6.3.3 Diagnostic Centres
    6.3.4 Homecare Settings
    6.3.5 Others
    6.4 Global Pulmonary Drug Delivery Systems Market by Region
    6.4.1 Market Overview
    6.4.2 North America
    6.4.3 Europe
    6.4.4 Asia Pacific
    6.4.5 Latin America
    6.4.6 Middle East and Africa
    7 North America Pulmonary Drug Delivery Systems Market
    7.1 Market Share by Country
    7.2 United States of America
    7.3 Canada
    8 Europe Pulmonary Drug Delivery Systems Market
    8.1 Market Share by Country
    8.2 United Kingdom
    8.3 Germany
    8.4 France
    8.5 Italy
    8.6 Others
    9 Asia Pacific Pulmonary Drug Delivery Systems Market
    9.1 Market Share by Country
    9.2 China
    9.3 Japan
    9.4 India
    9.5 ASEAN
    9.6 Australia
    9.7 Others
    10 Latin America Pulmonary Drug Delivery Systems Market
    10.1 Market Share by Country
    10.2 Brazil
    10.3 Argentina
    10.4 Mexico
    10.5 Others
    11 Middle East and Africa Pulmonary Drug Delivery Systems Market
    11.1 Market Share by Country
    11.2 Saudi Arabia
    11.3 United Arab Emirates
    11.4 Nigeria
    11.5 South Africa
    11.6 Others
    12 Patent Analysis
    12.1 Analysis by Type of Patent
    12.2 Analysis by Publication year
    12.3 Analysis by Issuing Authority
    12.4 Analysis by Patent Age
    12.5 Analysis by CPC Analysis
    12.6 Analysis by Patent Valuation
    12.7 Analysis by Key Players
    13 Grants Analysis
    13.1 Analysis by year
    13.2 Analysis by Amount Awarded
    13.3 Analysis by Issuing Authority
    13.4 Analysis by Grant Application
    13.5 Analysis by Funding Institute
    13.6 Analysis by NIH Departments
    13.7 Analysis by Recipient Organization
    14 Funding Analysis
    14.1 Analysis by Funding Instances
    14.2 Analysis by Type of Funding
    14.3 Analysis by Funding Amount
    14.4 Analysis by Leading Players
    14.5 Analysis by Leading Investors
    14.6 Analysis by Geography
    15 Partnership and Collaborations Analysis
    15.1 Analysis by Partnership Instances
    15.2 Analysis by Type of Partnership
    15.3 Analysis by Leading Players
    15.4 Analysis by Geography
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 INDIA CDSCO
    16.1.4 JAPAN PMDA
    16.1.5 Others
    17 Supplier Landscape
    17.1 Koninklijke Philips NV
    17.1.1 Financial Analysis
    17.1.2 Product Portfolio
    17.1.3 Demographic Reach and Achievements
    17.1.4 Mergers and Acquisition
    17.1.5 Certifications
    17.2 GlaxoSmithKline PLC
    17.2.1 Financial Analysis
    17.2.2 Product Portfolio
    17.2.3 Demographic Reach and Achievements
    17.2.4 Mergers and Acquisition
    17.2.5 Certifications
    17.3 3M
    17.3.1 Financial Analysis
    17.3.2 Product Portfolio
    17.3.3 Demographic Reach and Achievements
    17.3.4 Mergers and Acquisition
    17.3.5 Certifications
    17.4 Novartis AG
    17.4.1 Financial Analysis
    17.4.2 Product Portfolio
    17.4.3 Demographic Reach and Achievements
    17.4.4 Mergers and Acquisition
    17.4.5 Certifications
    17.5 Boehringer Ingelheim International GmbH
    17.5.1 Financial Analysis
    17.5.2 Product Portfolio
    17.5.3 Demographic Reach and Achievements
    17.5.4 Mergers and Acquisition
    17.5.5 Certifications
    17.6 AstraZeneca
    17.6.1 Financial Analysis
    17.6.2 Product Portfolio
    17.6.3 Demographic Reach and Achievements
    17.6.4 Mergers and Acquisition
    17.6.5 Certifications
    17.7 Cipla Inc.
    17.7.1 Financial Analysis
    17.7.2 Product Portfolio
    17.7.3 Demographic Reach and Achievements
    17.7.4 Mergers and Acquisition
    17.7.5 Certifications
    17.8 Merck & Co.
    17.8.1 Financial Analysis
    17.8.2 Product Portfolio
    17.8.3 Demographic Reach and Achievements
    17.8.4 Mergers and Acquisition
    17.8.5 Certifications
    17.9 GF Health Products Inc.
    17.9.1 Financial Analysis
    17.9.2 Product Portfolio
    17.9.3 Demographic Reach and Achievements
    17.9.4 Mergers and Acquisition
    17.9.5 Certifications
    17.10 Aerogen
    17.10.1 Financial Analysis
    17.10.2 Product Portfolio
    17.10.3 Demographic Reach and Achievements
    17.10.4 Mergers and Acquisition
    17.10.5 Certifications
    17.11 PARI GmbH
    17.11.1 Financial Analysis
    17.11.2 Product Portfolio
    17.11.3 Demographic Reach and Achievements
    17.11.4 Mergers and Acquisition
    17.11.5 Certifications
    17.12 Gilbert Technologies
    17.12.1 Financial Analysis
    17.12.2 Product Portfolio
    17.12.3 Demographic Reach and Achievements
    17.12.4 Mergers and Acquisition
    17.12.5 Certifications
    18 Global Pulmonary Drug Delivery Systems Market - Distribution Model (Additional Insight)
    18.1 Overview
    18.2 Potential Distributors
    18.3 Key Parameters for Distribution Partner Assessment
    19 Key Opinion Leaders (KOL) Insights (Additional Insight)
    20 Company Competitiveness Analysis (Additional Insight)
    20.1 Very Small Companies
    20.2 Small Companies
    20.3 Mid-Sized Companies
    20.4 Large Companies
    20.5 Very Large Companies
    21 Payment Methods (Additional Insight)
    21.1 Government Funded
    21.2 Private Insurance
    21.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us